TRPV2 Agonists in the Fontan Circulation

NCT03965351 PHASE4 COMPLETED Results posted

There are currently very few proven pharmacologic options available for these patients. The recent discovery of transient receptor potential vanilloid (TRPV) channels, particularly TRPV2 channels, in the cardiovascular system is promising as a potential pathway for pharmacologic intervention for Fontan patients. Probenecid, a drug best known as a treatment for gout or as a penicillin adjunct, acts as a TRPV2 agonist and has recently become the subject of study as a model therapy for the treatment of cardiomyopathy due to its positive inotropic and lusitropic effects. The purpose of this pilot study is to determine if probenecid will improve magnetic resonance (MRI) parameters of systolic and/or diastolic dysfunction as well as associated symptoms in patients with a Fontan circulation. The investigators will quantitatively assess functional improvement with pre- and post-treatment cardiopulmonary exercise testing.

Details

Lead sponsor	Children's Hospital Medical Center, Cincinnati
Phase	PHASE4
Status	COMPLETED
Enrolment	8
Start date	Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Fontan

Interventions

• Probenecid
• Placebo

Countries

United States